|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
4104.00
|
|
|
52-Week-Low (Rs.)
|
3050.15
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | 23,541.00 | 36,765.20 | 26,278.70 | 18,132.90 | 18,332.30 | Adjustment | 1,181.40 | 2,353.20 | 1,866.60 | 525.50 | 867.10 | Changes In working Capital | 4,473.00 | -13,718.90 | -2,345.20 | -2,114.00 | -4,729.60 | Cash Flow after changes in Working Capital | 29,195.40 | 25,399.50 | 25,800.10 | 16,544.40 | 14,469.80 | Cash Flow from Operating Activities | 24,479.50 | 19,101.60 | 19,470.50 | 12,084.70 | 9,640.60 | Cash Flow from Investing Activities | -27,067.50 | -21,954.00 | 753.40 | -813.80 | -6,842.40 | Cash Flow from Financing Activities | -7,965.90 | -5,315.00 | -339.70 | -10,912.50 | -2,459.40 | Net Cash Inflow / Outflow | -10,553.90 | -8,167.40 | 19,884.20 | 358.40 | 338.80 | Opening Cash & Cash Equivalents | 11,995.60 | 20,163.00 | 278.80 | -79.60 | -418.40 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 0 | 0 | 0 | 0 | 0 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | 0 | 0 | 0 | 0 | 0 | Closing Cash & Cash Equivalent | 1,441.70 | 11,995.60 | 20,163.00 | 278.80 | -79.60 |
|
|
|
|
|
|